---
title: "SOPH Jumps 2.67% on Strong Earnings, BLTE Drops 6.68% After Q4 Report"
canonical_url: https://www.stockexpertai.com/journal/2026-03-03/soph-jumps-267-on-strong-earnings-blte-drops-668-after-q4-report
last_updated: 2026-03-03T12:13:01.242Z
section: "Weekly Picks"
author: "Alex Sterling"
publisher: Stock Expert AI
tickers: SOPH, BLTE, COIN, BTC, ETH, XRP, API, INSW, BLKB, RL, KEYS, AAPL, MSFT, GOOGL
content_type: journal-article
---

# SOPH Jumps 2.67% on Strong Earnings, BLTE Drops 6.68% After Q4 Report

## The Take
- Focus on earnings growth and strategic pivots, but always assess risk in volatile markets. Watch SOPH, BLTE, and COIN for potential entries.

_This week's picks focus on earnings reports, AI pivots, and potential investment opportunities in volatile markets._

Markets are signaling something important today. Earnings reports are driving individual stock movements, while broader market sentiment remains cautiously optimistic. This week's picks highlight companies undergoing significant transitions or demonstrating strong growth in key sectors. Let's dive into a few names on our watchlist.

First up is SOPHiA GENETICS (SOPH), which reported a 22% year-over-year increase in fourth-quarter revenue, reaching $21.7 million. Full-year revenue also saw a healthy 19% jump to $77.3 million. While the company reported an IFRS net loss of $79.0 million for the full year, the growth momentum and advancements in AI-driven precision medicine make SOPH an interesting play. Consider entry points around the current level of $4.62, but be mindful of the company's ongoing losses and the competitive landscape.

On the other end of the spectrum is Belite Bio, Inc (BLTE), which experienced a -6.68% drop. The company is focused on developing therapies for inherited retinal diseases, with its lead product candidate CNV500 in clinical trials. While the long-term potential is there, the stock is subject to clinical trial risks and regulatory hurdles. Investors should proceed with caution and closely monitor the progress of CNV500. A potential entry point could be considered after further review of their Q4 earnings call transcript, but be aware of the inherent risks in biopharmaceutical development.

Finally, we're watching Core Scientific's (no ticker in VDB) strategic pivot from Bitcoin mining to AI-focused data centers. While they will liquidate BTC holdings, Bitcoin itself is up with BTC at $67896.00. This move highlights the growing demand for AI infrastructure. The company's actions could impact the price of Bitcoin. While Core Scientific isn't directly tradable based on available data, COIN, Coinbase, could be a beneficiary as Core Scientific places its current Bitcoin block rewards through Coinbase Prime. COIN is up +5.34% at $185.24.

Keep these levels in mind as you navigate today's session.

## Related Tickers
- [SOPH](https://www.stockexpertai.com/stock/soph)
- [BLTE](https://www.stockexpertai.com/stock/blte)
- [COIN](https://www.stockexpertai.com/stock/coin)
- [BTC](https://www.stockexpertai.com/stock/btc)
- [ETH](https://www.stockexpertai.com/stock/eth)
- [XRP](https://www.stockexpertai.com/stock/xrp)
- [API](https://www.stockexpertai.com/stock/api)
- [INSW](https://www.stockexpertai.com/stock/insw)
- [BLKB](https://www.stockexpertai.com/stock/blkb)
- [RL](https://www.stockexpertai.com/stock/rl)
- [KEYS](https://www.stockexpertai.com/stock/keys)
- [AAPL](https://www.stockexpertai.com/stock/aapl)
- [MSFT](https://www.stockexpertai.com/stock/msft)
- [GOOGL](https://www.stockexpertai.com/stock/googl)

## Frequently Asked Questions

### Why did SOPH stock jump?
SOPH stock increased due to a strong earnings report, with a 22% year-over-year increase in fourth-quarter revenue. The company's advancements in AI-driven precision medicine also contributed to investor interest. However, investors should be mindful of the company's ongoing losses.

### Why did BLTE stock drop?
BLTE stock dropped following its Q4 report, likely due to investor concerns about clinical trial risks and regulatory hurdles associated with its lead product candidate, CNV500. Investors are advised to proceed with caution and monitor the progress of the clinical trials.

---
_AI-generated under human editorial supervision. Educational research, not financial advice._